Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
Phase 2
Recruiting
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- Drug: KPI-012 Vehicle
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Combangio, Inc
- Target Recruit Count
- 2
- Registration Number
- NCT05727878
- Locations
- 🇵🇷
Principal Investigator, San Juan, Puerto Rico
🇺🇸Principal investigator, Durham, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath